The NF-B subunit RelB regulates the migration and invasion abilities and the radio-sensitivity of prostate cancer cells

International Journal of Oncology

Volumn 49, Issue 1, 2016, Pages 381-392

  Wang, Jie ^a   Yi, Suqin ^b   Zhou, Jun ^a   Zhang, Youtao ^a   Guo, Feng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b First People's Hospital of Yancheng   (China)

Author keywords

Invasion; Migration; Prostate cancer cell; Radio sensitivity; RelB

Indexed keywords

BETA1 INTEGRIN; PROTEASOME INHIBITOR; PROTEIN BCL 2; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR RELB; RELB PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL FUNCTION; DU145 CELL LINE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; METASTASIS INHIBITION; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOSENSITIVITY; TUMOR INVASION; BIOSYNTHESIS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MALE; PATHOLOGY; PROSTATIC NEOPLASMS; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTIGENS, CD29; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEASOME INHIBITORS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION TOLERANCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELB;

EID: 84978409950     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2016.3500     Document Type: Article

References (38)

1. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer statistics for Hispanics/ Latinos, 2015. CA Cancer J Clin 65: 457-480, 2015.
2. Napetschnig J and Wu H: Molecular basis of NF-B signaling. Annu Rev Biophys 42: 443-468, 2013.
3. Weih F and Caamaño J: Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol Rev 195: 91-105, 2003.
4. Perkins ND: The diverse and complex roles of NF-B subunits in cancer. Nat Rev Cancer 12: 121-132, 2012.
5. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
6. Suh J and Rabson AB: NF-kappaB activation in human prostate cancer: Important mediator or epiphenomenon? J Cell Biochem 91: 100-117, 2004.
7. Lessard L, Bégin LR, Gleave ME, Mes-Masson AM and Saad F: Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: An immunohistochemical study. Br J Cancer 93: 1019-1023, 2005.
8. Guo F, Kang S, Zhou P, Guo L, Ma L and Hou J: Maspin expression is regulated by the non-canonical NF-B subunit in androgeninsensitive prostate cancer cell lines. Mol Immunol 49: 8-17, 2011.
9. Lessard L, Saad F, Le Page C, Diallo JS, Péant B, Delvoye N and Mes-Masson AM: NF-kappaB2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. Cell Signal 19: 1093-1100, 2007.
10. Holley AK, Xu Y, St Clair DK and St Clair WH: RelB regulates manganese superoxide dismutase gene and resistance to ionizing radiation of prostate cancer cells. Ann NY Acad Sci 1201: 129-136, 2010.
11. Xu Y, Fang F, St Clair DK, Josson S, Sompol P, Spasojevic I and St Clair WH: Suppression of RelB-mediated manganese superoxide dismutase expression reveals a primary mechanism for radiosensitization effect of 1alpha,25-dihydroxyvitamin D(3) in prostate cancer cells. Mol Cancer Ther 6: 2048-2056, 2007.
12. Mineva ND, Wang X, Yang S, Ying H, Xiao ZX, Holick MF and Sonenshein GE: Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. J Cell Physiol 220: 593-599, 2009.
13. Shukla S, Kanwal R, Shankar E, Datt M, Chance MR, Fu P, MacLennan GT and Gupta S: Apigenin blocks IKK activation and suppresses prostate cancer progression. Oncotarget 6: 31216-31232, 2015.
14. Luo JL, Tan W, Ricono JM, Korchynskyi O, Zhang M, Gonias SL, Cheresh DA and Karin M: Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 446: 690-694, 2007.
15. Guo F, Sun A, Wang W, He J, Hou J, Zhou P and Chen Z: TRAF1 is involved in the classical NF-kappaB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells. Mol Immunol 46: 2441-2448, 2009.
16. Xu J, Zhou P, Wang W, Sun A and Guo F: RelB, together with RelA, sustains cell survival and confers proteasome inhibitor sensitivity of chronic lymphocytic leukemia cells from bone marrow. J Mol Med Berl 92: 77-92, 2014.
17. Ranuncolo SM, Pittaluga S, Evbuomwan MO, Jaffe ES and Lewis BA: Hodgkin lymphoma requires stabilized NIK and constitutive RelB expression for survival. Blood 120: 3756-3763, 2012.
18. Xu Y, Josson S, Fang F, Oberley TD, St Clair DK, Wan XS, Sun Y, Bakthavatchalu V, Muthuswamy A and St Clair WH: RelB enhances prostate cancer growth: Implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity. Cancer Res 69: 3267-3271, 2009.
19. Xu Y, Fang F, St Clair DK and St Clair WH: Inverse relationship between PSA and IL-8 in prostate cancer: An insight into a NF-B-mediated mechanism. PLoS One 7: e32905, 2012.
20. Cormier F, Monjanel H, Fabre C, Billot K, Sapharikas E, Chereau F, Bordereaux D, Molina TJ, Avet-Loiseau H and Baud V : Frequent engagement of RelB activation is critical for cell survival in multiple myeloma. PLoS One 8: e59127, 2013.
21. Zhou J, Hualong Q, Zhou P and Guo F: Different maspin functions in the lung adenocarcinoma A549 and SPC-A1 cell lines. Int J Mol Med 36: 1440-1448, 2015.
22. Wang X, Belguise K, O'Neill CF, Sánchez-Morgan N, Romagnoli M, Eddy SF, Mineva ND, Yu Z, Min C, Trinkaus-Randall V, et al: RelB NF-kappaB represses estrogen receptor alpha expression via induction of the zinc finger protein Blimp1. Mol Cell Biol 29: 3832-3844, 2009.
23. Yu Z, Sato S, Trackman PC, Kirsch KH and Sonenshein GE : Blimp1 activation by AP-1 in human lung cancer cells promotes a migratory phenotype and is inhibited by the lysyl oxidase propeptide. PLoS One 7: e33287, 2012.
24. Wang X, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D and Sonenshein GE: Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 9: 470-478, 2007.
25. Peeters MC, Fokkelman M, Boogaard B, Egerod KL, van de Water B, IJzerman AP and Schwartz TW: The adhesion G protein-coupled receptor G2 (ADGRG2/GPR64) constitutively activates SRE and NFB and is involved in cell adhesion and migration. Cell Signal 27: 2579-2588, 2015.
26. Authier H, Billot K, Derudder E, Bordereaux D, Rivière P, Rodrigues-Ferreira S, Nahmias C and Baud V: IKK phosphorylates RelB to modulate its promoter specificity and promote fibroblast migration downstream of TNF receptors. Proc Natl Acad Sci USA 111: 14794-14799, 2014.
27. Wang XM, Li J, Yan MX, Liu L, Jia DS, Geng Q, Lin HC, He XH, Li JJ and Yao M: Integrative analyses identify osteopontin, LAMB3 and ITGB1 as critical pro-metastatic genes for lung cancer. PLoS One 8: e55714, 2013.
28. Lee YC, Jin JK, Cheng CJ, Huang CF, Song JH, Huang M, Brown WS, Zhang S, Yu-Lee LY, Yeh ET, et al: Targeting constitutively activated 1 integrins inhibits prostate cancer metastasis. Mol Cancer Res 11: 405-417, 2013.
29. Ravenhill L, Wagstaff L, Edwards DR, Ellis V and Bass R: G-helix of maspin mediates effects on cell migration and adhesion. J Biol Chem 285: 36285-36292, 2010.
30. Saito T, Sasaki CY, Rezanka LJ, Ghosh P and Longo DL: p52-independent nuclear translocation of RelB promotes LPS-induced attachment. Biochem Biophys Res Commun 391: 235-241, 2010.
31. Xie BX, Zhang H, Yu L, Wang J, Pang B, Wu RQ, Qian XL, Li SH, Shi QG, Wang LL, et al: The radiation response of androgen-refractory prostate cancer cell line C4-2 derived from androgen-sensitive cell line LNCaP. Asian J Androl 12: 405-414, 2010.
32. Xu Y, Fang F, St Clair DK, Sompol P, Josson S and St Clair WH: SN52, a novel nuclear factor-kappaB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol Cancer Ther 7: 2367-2376, 2008.
33. Zhu L, Zhu B, Yang L, Zhao X, Jiang H and Ma F: RelB regulates Bcl-xL expression and the irradiation-induced apoptosis of murine prostate cancer cells. Biomed Rep 2: 354-358, 2014.
34. Harima Y, Harima K, Shikata N, Oka A, Ohnishi T and Tanaka Y: Bax and Bcl-2 expressions predict response to radiotherapy in human cervical cancer. J Cancer Res Clin Oncol 124: 503-510, 1998.
35. Xu Y, Fang F, Sun Y, St Clair DK and St Clair WH: RelBdependent differential radiosensitization effect of STI571 on prostate cancer cells. Mol Cancer Ther 9: 803-812, 2010.
36. Manna S, Singha B, Phyo SA, Gatla HR, Chang TP, Sanacora S, Ramaswami S and Vancurova I: Proteasome inhibition by bortezomib increases IL-8 expression in androgen-independent prostate cancer cells: The role of IKK?. J Immunol 191: 2837-2846, 2013.
37. Singha B, Gatla HR, Manna S, Chang TP, Sanacora S, Poltoratsky V, Vancura A and Vancurova I: Proteasome inhibition increases recruitment of IB kinase (IKK), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells. J Biol Chem 289: 2687-2700, 2014.
38. Garber K: Gene mutation revelation points to new target for myeloma treatment, studies say. J Natl Cancer Inst 99: 1362-1364, 2007.